News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Murray Epstein, MD

Articles by Murray Epstein, MD

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan Golestane

August 31st 2016

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Nancy L. Reaven, MA,Susan E. Funk, MBA,Karen J. McGaughey, PhD,Nina Oestreicher, PhD,John Knispel, MD

September 16th 2015

Latest Updated Articles

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
Published: September 16th 2015 | Updated:
Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors
Published: August 31st 2016 | Updated:

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text